CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-27 | Kumar Neil Director | Grant or award · Stock Option (Right to Buy) | +33,417 | 33,417 | ||
| 2026-03-20 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +15,000 | $10.42 | $156K | 15,000 |
| 2026-03-20 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −6,161 | $48.20 | $297K | 8,839 |
| 2026-03-20 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −3,795 | $49.32 | $187K | 5,044 |
| 2026-03-20 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −5,044 | $50.02 | $252K | 0 |
| 2026-03-20 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 252,407 | ||
| 2026-03-10 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +30,000 | $10.42 | $313K | 30,000 |
| 2026-03-10 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −29,652 | $50.45 | $1.5M | 348 |
| 2026-03-10 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −348 | $51.02 | $18K | 0 |
| 2026-03-10 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 267,407 | ||
| 2026-03-02 | Bachrodt Amy SVP, Finance | Option exercise 10b5-1 | +5,000 | $10.42 | $52K | 17,965 |
| 2026-03-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −1,300 | $44.44 | $58K | 16,665 |
| 2026-03-02 | Bachrodt Amy SVP, Finance | Sale 10b5-1 | −3,700 | $45.47 | $168K | 12,965 |
| 2026-03-02 | Bachrodt Amy SVP, Finance | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 36,333 | ||
| 2026-03-02 | Bachrodt Amy SVP, Finance | Grant or award · Stock Option (Right to Buy) 10b5-1 | +32,000 | 32,000 | ||
| 2026-03-02 | Bachrodt Amy SVP, Finance | Grant or award · Restricted Stock Units 10b5-1 | +16,000 | 16,000 | ||
| 2026-03-02 | Bernstein Harold President, R&D & CMO | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2026-03-02 | Bernstein Harold President, R&D & CMO | Grant or award · Restricted Stock Units | +24,000 | 24,000 | ||
| 2026-03-02 | Dandekar Atul CSBO | Grant or award · Stock Option (Right to Buy) 10b5-1 | +38,000 | 38,000 | ||
| 2026-03-02 | Dandekar Atul CSBO | Grant or award · Restricted Stock Units 10b5-1 | +19,000 | 19,000 |
Page 7 of 14 · 267 trades